Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
Types of RNA01:20

Types of RNA

6.3K
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
6.3K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Lineage-restricted dependency on an oncofetal SNHG29-IGF2BP1 RNA axis in acute megakaryoblastic leukemia.

Leukemia·2026
Same author

Pharmacological clearance of senescent cells reduces inflammation, endothelial damage and cardiac fibrosis in HFpEF.

Cardiovascular research·2025
Same author

An interplay of non-coding RNAs regulates <i>CDH13</i> expression and affects endothelial function and coronary artery disease risk.

Research square·2025
Same author

Aging-regulated PNUTS maintains endothelial barrier function via SEMA3B suppression.

Communications biology·2024
Same author

DLC1 promotes mechanotransductive feedback for YAP via RhoGAP-mediated focal adhesion turnover.

Journal of cell science·2024
Same author

HDAC1/2 inhibitor therapy improves multiple organ systems in aged mice.

iScience·2024

関連する実験動画

Updated: Sep 9, 2025

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

9.2K

心血管疾患に対する長い非コーディングRNAベースの治療法

Noelia Bellon Quinones1,2, Ruggero Belluomo3,4, Rio P Juni5,6

  • 1Institute for Cardiovascular Regeneration, Centre for Molecular Medicine, Goethe University, Frankfurt Am Main, Germany.

Journal of cardiovascular translational research
|September 3, 2025
PubMed
まとめ

長い非コーディングRNA (lncRNAs) は,心血管疾患 (CVD) の主要な調節因子である. 研究では バイオマーカーや治療標的としての可能性が示され 進歩した遺伝子治療は 将来の治療に有望であることを示しています

キーワード:
心血管疾患遺伝子療法長い非コーディングRNA (lncRNAs)RNA療法

さらに関連する動画

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR
13:04

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR

Published on: March 1, 2019

9.0K
Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

11.4K

関連する実験動画

Last Updated: Sep 9, 2025

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

9.2K
Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR
13:04

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR

Published on: March 1, 2019

9.0K
Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

11.4K

科学分野:

  • 分子生物学
  • 心血管研究
  • 遺伝学

背景:

  • 心血管疾患 (CVD) は世界の主要な健康問題であり,新しい治療方法の必要性を引き起こしています.
  • 長い非コーディングRNA (lncRNAs) は,心臓血管の健康と疾患に関連する細胞過程における遺伝子発現の重要な調節体としてますます認識されています.

研究 の 目的:

  • 心血管疾患の病原性における lncRNA の機能的役割を検討する.
  • lncRNAの診断用バイオマーカーおよび治療用ターゲットとしての可能性を調査する.
  • lncRNAベースの心臓血管治療の遺伝子療法と投与戦略の進歩について議論する.

主な方法:

  • 心血管疾患における lncRNA機能に関する研究の文献レビュー.
  • 現在のRNAターゲティング技術 (例えば,反意味オリゴヌクレオチド,siRNA,CRISPR) の分析.
  • lncRNA療法のためのウイルスおよび非ウイルス輸送システムの評価.

主要な成果:

  • lncRNAsは,高縮,線維症,炎症,血管再構成を含む主要なCVDプロセスに関与しています.
  • 新興のRNAターゲティング技術は 心血管疾患の治療の可能性を秘めています
  • lncRNAベースの治療法の臨床翻訳には,特に投与方法に関する課題が残っています.

結論:

  • lncRNAは心臓血管疾患の新たな診断と治療戦略を開発する有望な分野です.
  • lncRNAの生物学と伝達システムの最適化に関するさらなる研究は,臨床応用に不可欠である.
  • lncRNAベースの治療は 心血管医学を大幅に進歩させる可能性を秘めています